ACTA1 and renal fibrosis: CC-930 treatment had no significant effect on renal fibrosis on day 22 of AAN in terms of collagen IV deposition and mRNA levels of collagen III and IV, and α-SMA/Acta2 (Figures 8C–G), although there was a small reduction in the mRNA levels of TGF-β1 (Figure 8H).